康缘药业：公司构建“AI驱动的活性物质发现”“药物筛选评价与新药研制”等技术体系

Core Viewpoint - The company is actively embracing "AI + smart manufacturing" to inject new vitality into pharmaceutical innovation, responding to national strategies for developing new productive forces [1] Group 1: R&D Innovations - The company has established an "AI-driven active substance discovery" and "drug screening evaluation and new drug development" technical system [1] - The KYS2301 gel utilizes an AI drug discovery platform with deep learning algorithms to analyze vast compound data, significantly shortening the preclinical research cycle [1] - Exploratory research is being conducted in AI-enabled traditional Chinese medicine (TCM) development, focusing on discovering effective substances, identifying potential indications, and optimizing compound analysis [1] Group 2: Manufacturing Advancements - The company has pioneered a smart manufacturing technology system centered on effective ingredient groups, establishing the first intelligent production factory for TCM in China [1] - The self-developed Pharmaceutical Knowledge System (PKS) overcomes the bottleneck of big data application in the pharmaceutical industry, transitioning TCM production from traditional experience-based methods to precise and intelligent processes [1] Group 3: Future Directions - The company plans to continue deepening the application of AI technology across the entire chain of R&D, production, and quality control, aiming for innovative outcomes that benefit investors [1]